Realcan Pharmaceutical Group Co.Ltd(002589)
Independent directors’ comments on the 18th meeting of the 4th board of directors
Independent opinions on relevant matters
As an independent director of Realcan Pharmaceutical Group Co.Ltd(002589) (hereinafter referred to as the “company”), we undertake to perform our duties independently in accordance with the stock listing rules of Shenzhen Stock Exchange (revised in 2022), the guiding opinions on the establishment of independent director system in listed companies and other relevant laws and regulations, as well as the relevant provisions of the company’s independent director working system, and are not subject to the supervision of the company’s major shareholders After carefully reviewing the relevant documents of the 18th meeting of the 4th board of directors of the company, the independent opinions on relevant matters are as follows: I. independent opinions on the engagement of 2021 audit institution by the company
After verification, tianyuanquan Certified Public Accountants (special general partnership) is qualified in the securities industry. During the practice, it adheres to the principle of independent audit, and the professional reports issued for the company are objective and fair. We agree to continue to hire tianyuanquan Certified Public Accountants (special general partnership) as the audit institution of the company in 2021, And agreed to submit this proposal to the first extraordinary general meeting of shareholders of the company in 2022 for deliberation. 2、 Proposal on using idle self owned funds to purchase financial products
After reviewing the proposal on using idle self owned funds to purchase financial products, we believe that the decision-making procedure for the company to review the proposal is in accordance with the stock listing rules of Shenzhen Stock Exchange (revised in 2022) and the provisions of the articles of association and other relevant laws, regulations and normative documents. The use of self owned funds to purchase financial products can improve the company’s fund use efficiency and increase the company’s fund income, will not have an adverse impact on the company’s business activities, is in line with the interests of listed companies and all shareholders, and does not damage the interests of the company and all shareholders, especially small and medium-sized shareholders. We agree to the matter.
[there is no text on this page, which is the signature page of Realcan Pharmaceutical Group Co.Ltd(002589) independent directors’ independent opinions on relevant matters of the 18th meeting of the Fourth Board of directors] signatures of all independent directors:
Wu binliu Xijun Yu Jianqing
January 21, 2022
